European Ancestry as a Risk Factor for Atrial Fibrillation in African Americans

Gregory M. Marcus, MD, MAS; Alvaro Alonso, MD, PhD; Carmen A. Peralta, MD, MAS; Guillaume Lettre, PhD; Eric Vittinghoff, PhD; Steven A. Lubitz, MD; Ervin R. Fox, MD, MPH; Yamini S. Levitzky, MD, MPH; Reena Mehra, MD, MS; Kathleen F. Kerr, PhD; Rajat Deo, MD; Nona Sotoodehnia, MD, MPH; Meggie Akyylbekova, MS, MD; Patrick T. Ellinor, MD, PhD; Dina N. Paltoo, MPH, PhD; Elsayed Z. Soliman, MD, MSc, MS; Emelia J. Benjamin, MD, ScM; Susan R. Heckbert, MD, PhD; for the Candidate-Gene Association Resource (CARe) Study

Background—Despite a higher burden of standard atrial fibrillation (AF) risk factors, African Americans have a lower risk of AF than whites. It is unknown whether the higher risk is due to genetic or environmental factors. Because African Americans have varying degrees of European ancestry, we sought to test the hypothesis that European ancestry is an independent risk factor for AF.

Methods and Results—We studied whites (n=4543) and African Americans (n=822) in the Cardiovascular Health Study (CHS) and whites (n=10 902) and African Americans (n=3517) in the Atherosclerosis Risk in Communities (ARIC) Study (n=3517). Percent European ancestry in African Americans was estimated with 1747 ancestry informative markers from the Illumina custom ITMAT-Broad-CARe array. Among African Americans without baseline AF, 120 of 804 CHS participants and 181 of 3517 ARIC participants developed incident AF. A meta-analysis from the 2 studies revealed that every 10% increase in European ancestry increased the risk of AF by 13% (hazard ratio, 1.13; 95% confidence interval, 1.03 to 1.23; P=0.007). After adjustment for potential confounders, European ancestry remained a predictor of incident AF in each cohort alone, with a combined estimated hazard ratio for each 10% increase in European ancestry of 1.17 (95% confidence interval, 1.07 to 1.23; P=0.001). A second analysis using 3192 ancestry informative markers from a genome-wide Affymetrix 6.0 array in ARIC African Americans yielded similar results.

Conclusions—European ancestry predicted risk of incident AF. Our study suggests that investigating genetic variants contributing to differential AF risk in individuals of African versus European ancestry will be informative. (Circulation. 2010;122:2009-2015.)

Key Words: ancestry ■ African Americans ■ atrial fibrillation ■ genetics

Although atrial fibrillation (AF) is the commonest sustained arrhythmia, its origin remains incompletely understood.1 African Americans appear to be at a particularly low risk of AF,2,3 a finding that is paradoxical considering that African Americans have a higher prevalence of many of the risk factors known to increase the likelihood of AF. Compared with whites, African Americans are more frequently hypertensive4 and more commonly exhibit heart failure,5 diabetes mellitus,6 and a larger body mass index (BMI).7,8 Whether environmental or genetic, it would therefore appear that there are novel factors either protecting African Americans from AF or making whites especially prone to AF that remain undetermined. To determine whether genetic differences are responsible, it would be useful to know if European ancestry is an independent risk factor for AF.
Clinical Perspective on p 2015

African Americans are a genetically heterogeneous group comprising both African and European ancestral genomes. Admixture analysis uses ancestry informative markers (AIMs), or genetic markers known to have large allele frequency differences between ancestral populations, to determine the percent European or African ancestry in a given individual. Genetic admixture analysis provides a method to investigate whether complex phenotypes may be associated with genetic ancestral background in admixed populations. Thus, genetic heterogeneity of African Americans provides a unique opportunity to determine whether ancestry is an important factor in predisposing individuals to AF. Because AF is more common in whites, we hypothesized that increasing European ancestry would be associated with elevated risk of AF in African Americans. Therefore, we sought to understand whether genetic ancestry is associated with incident AF in African American participants enrolled in 2 large cohorts: the Cardiovascular Health Study (CHS) and the Atherosclerosis Risk in Communities (ARIC) Study.

Methods

The CHS

The design of the CHS has previously been described. Briefly, between 1989 and 1990, 5201 men and women ≥65 years of age were enrolled using random samples from Medicare eligibility lists from 4 communities: Forsyth County, NC; Sacramento County, Calif; Washington County, Md; and Pittsburgh, Pa. A second cohort of 687 African American participants was enrolled between 1992 and 1993. All participants underwent a comprehensive examination at baseline, which included a thorough medical history, measurement of height and weight, laboratory testing, a 12-lead ECG, current medication use, statin use, diabetes mellitus, weight, and height were measured with standardized methods. Baseline alcohol intake was defined as a blood pressure of 140/90 mm Hg or current use of antihypertensive medication, or a fasting blood sugar ≥126 mg/dL. ECG diagnosis of left ventricular hypertrophy was determined by the Minnesota Code. A history of myocardial infarction at baseline was determined by self-report and confirmed by components of the baseline examination or, if necessary, by a validation protocol that included either the review of medical records or surveys of treating physicians. Cases of AF were identified by ECGs obtained at annual study visits through 1999 and hospital discharge diagnosis during a median of 10 years of follow-up.

The ARIC Study

The ARIC Study has previously been described. Briefly, this is a population-based prospective study of cardiovascular disease in a cohort of 15,792 participants 45 to 64 years of age at enrollment sampled from 4 US communities: suburbs of Minneapolis, Minn; Washington County, Md; Jackson, Miss; and Forsyth County, NC, from 1987 to 1989. After an initial assessment, study participants were examined 3 additional times at intervals of roughly 3 years. In addition, participants were contacted yearly by phone to obtain information about hospital admissions and to ascertain vital status. At baseline, cigarette smoking, blood pressure, antihypertensive medication use, statin use, diabetes mellitus, weight, and height were measured with standardized methods. Baseline alcohol intake was determined and quantified into grams per week. Hypertension was defined as a blood pressure of ≥140/90 mm Hg or current use of antihypertensive medication. ECG-diagnosed left ventricular hypertrophy was considered present based on Cornell voltage criteria. History of myocardial infarction at baseline was defined as a self-reported history of a physician-diagnosed myocardial infarction or evidence of previous myocardial infarction in the baseline ECG. The methods used for AF ascertainment have previously been described in detail. Briefly, AF diagnoses were obtained from ECGs at baseline and the 3 follow-up visits, from International Classification of Diseases, ninth revision (ICD-9) codes from hospital discharge records, and ICD-9 and ICD-10 codes from death certificates. Two previous analyses within this population validated the diagnosis of incident AF based on hospital discharge records.

Those with AF on the baseline ECG were excluded from analysis of incident AF. The study was approved by Institutional Review boards at each participating center. Written informed consent was obtained from all participants.

AIM Selection

AIMs were assessed with the Illumina custom ITMAT-Broad-CARE (IBC) array (San Diego, Calif) in both cohorts. AIMs from the Affymetrix genome-wide human single-nucleotide polymorphism (SNP) array (Santa Clara, Calif) were also analyzed in ARIC.

Illumina IBC Array

As part of the Candidate-Gene Association Resource (CARe) study, a cardiovascular gene-centric 50,000-SNP array, called the IBC array, was previously developed and has been described in detail. AIMS (n = 1747) passing genotype quality-control criteria were used to estimate African versus European global ancestry. These SNPs were based on panels generated previously, excluding SNPs failing Hardy-Weinberg equilibrium (P > 0.01). The IBC AIMs are listed within the IBC resource site (http://bmic.upenn.edu/cvdsnp/updates/ancestry_informative_markers-ibc-v1.xls). Percent global European ancestry was estimated in African Americans from both cohorts from these AIMs using the structure 2.3.1 software under the default parameters. Unrelated Northern European (CEU) and Western African (YRI) samples from the HapMap Project were also genotyped on the IBC array and included in this analysis to predefine the parental clusters.

Affymetrix 6.0 Array

After removal of related pairs and outlier samples determined by quality-control procedures with EIGENSOFT, 756 Western African samples and 1178 European American samples were used as parental samples to select the AIMs from the Affymetrix 6.0 genome-wide genotyping platform. The SmartPCA software confirmed that the leading eigenvector reflected genetic differences between Europe and West Africa. A greedy algorithm was used to produce a list of SNPs at least 0.5 cM apart from each other, chosen to have large SNP loadings (the loading is a score of how much a SNP contributes to a given eigenvector), producing a list of 4917 SNPs. A check on pairs of markers for detectable linkage disequilibrium was then performed: a statistic X, with a χ2 distribution with 1 df, was computed at random, and any pair exhibiting a genetic distance of d cM or less was declared to be in linkage disequilibrium if X > 0.02d. For such a pair, the less informative SNP was deleted. This strategy produced 3192 unlinked AIMs. Global European ancestry was estimated in African Americans enrolled in ARIC from these AIMs using the ANCESTRYMAP program under the default parameters. The CARe project did not genotype the CHS African American cohort on Affymetrix 6.0.

Statistical Analyses

Normally distributed variables are presented as mean ± SD and were compared by use of t tests. Continuous variables that were not normally distributed are presented as medians and interquartile ranges (IQRs) and were compared by use of the Wilcoxon rank-sum test. Categorical variables were compared by use of the χ2 test. A Cox proportional-hazards model was used to assess predictors of incident AF. Potential confounders were added to the multivariable Cox proportional-hazards model based on previously established covariates known to be associated with African American race and...
AF. We assessed the log-linearity of the association between percent European ancestry and risk of AF using restricted cubic splines. Specifically, we used a χ² test for the joint effect of the 3 nonlinear spline components, adjusting for the linear effect. No evidence for nonlinear response was found (all \( P > 0.66 \)); therefore, European ancestry was analyzed as a continuous variable. Hazard ratios (HRs) are expressed as point estimates and 95% confidence intervals (CIs).

A random-effects meta-analytic method was used to calculate a pooled estimate of the unadjusted and adjusted HRs for percent European ancestry. This method averages the HRs from each study on the log scale, weighted by the inverse of the variance of each estimate, and calculates conservative CIs under the assumption that the true effects in each study arise from a normal distribution. Heterogeneity of the study-specific estimates from ARIC and CHS was assessed with the Q statistic.²⁶ Stata version 11 (College Station, Tex) was used to perform statistical analyses. A 2-tailed value of \( P < 0.05 \) was considered statistically significant.

**Results**

**Racial Differences and Cardiovascular Risk Factors**

In CHS, of the 5365 participants included in the CARe study, 4543 were white and 822 were African American. Of the 14 419 ARIC participants included in the CARe study, 10 902 were white and 3517 were African American. In both cohorts, African Americans were younger than whites in both cohorts and were more often female (Table 1). In both cohorts, compared with their white counterparts, African American participants had a higher average BMI, and a larger proportion had hypertension, diabetes mellitus, heart failure, and ECG evidence of left ventricular hypertrophy. One hundred thirty-three white (3%) and 12 African American (2%) CHS participants had AF on their baseline ECG (\( P = 0.018 \)) and 27 white (0.3%) and 6 African American (0.2%) ARIC CARe participants had AF on their baseline ECG (\( P = 0.41 \)). These participants with prevalent AF were excluded from the incident AF analyses.

In CHS, a total of 1172 incident cases of AF were identified over a median 10 years of follow-up (IQR, 6 to 13 years). In ARIC, a total of 1068 incident cases of AF were observed over a median 16 years of follow-up (IQR, 15 to 17 years). In both cohorts, those with incident AF were older, were more often male, and more frequently exhibited hypertension, diabetes mellitus, heart failure, left ventricular hypertrophy, and a history of myocardial infarction (Table 2). Increasing BMI was also associated with AF in ARIC. In both cohorts, African Americans had a significantly lower risk of AF (Table 2), a difference that was more pronounced after adjustment for age, sex, BMI, hypertension, diabetes mellitus, heart failure, left ventricular hypertrophy, history of myocardial infarction, and study site. In CHS, African Americans

<table>
<thead>
<tr>
<th>Baseline Characteristic</th>
<th>CHS</th>
<th>P</th>
<th>ARIC</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>n</td>
<td>African Americans</td>
<td>822</td>
<td>4543</td>
<td></td>
</tr>
<tr>
<td>Age, y</td>
<td>73±6</td>
<td>0.46</td>
<td>53±6</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>BMI, kg/m²</td>
<td>29±6</td>
<td>&lt;0.0001</td>
<td>30±6</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Male, n (%)</td>
<td>310 (38)</td>
<td>0.001</td>
<td>1310 (37)</td>
<td>0.001</td>
</tr>
<tr>
<td>Hypertension, n (%)</td>
<td>604 (74)</td>
<td>&lt;0.0001</td>
<td>1942 (56)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Diabetes mellitus, n (%)</td>
<td>196 (25)</td>
<td>&lt;0.0001</td>
<td>675 (20)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Heart failure, n (%)</td>
<td>55 (7)</td>
<td>0.006</td>
<td>231 (7)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>LVH, n (%)</td>
<td>73 (9)</td>
<td>&lt;0.0001</td>
<td>180 (5)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>MI, n (%)</td>
<td>67 (8)</td>
<td>0.12</td>
<td>133 (4)</td>
<td>0.29</td>
</tr>
</tbody>
</table>

Table 1. Baseline Differences Between African Americans and Whites Enrolled in ARIC and CHS

<table>
<thead>
<tr>
<th>Predictor</th>
<th>HR</th>
<th>95% CI</th>
<th>P</th>
<th>Predictor</th>
<th>HR</th>
<th>95% CI</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (per 1 y)</td>
<td>1.08</td>
<td>1.07–1.09</td>
<td>&lt;0.001</td>
<td>1.12</td>
<td>1.11–1.13</td>
<td>&lt;0.0001</td>
<td></td>
</tr>
<tr>
<td>BMI (per 1 kg/m²)</td>
<td>1.01</td>
<td>1.01–1.02</td>
<td>0.21</td>
<td>1.04</td>
<td>1.03–1.05</td>
<td>&lt;0.0001</td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>1.59</td>
<td>1.42–1.78</td>
<td>&lt;0.0001</td>
<td>1.73</td>
<td>1.53–1.96</td>
<td>&lt;0.0001</td>
<td></td>
</tr>
<tr>
<td>Hypertension</td>
<td>1.50</td>
<td>1.33–1.70</td>
<td>&lt;0.0001</td>
<td>2.11</td>
<td>1.87–2.38</td>
<td>&lt;0.0001</td>
<td></td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>1.53</td>
<td>1.32–1.78</td>
<td>&lt;0.0001</td>
<td>2.09</td>
<td>1.79–2.45</td>
<td>&lt;0.0001</td>
<td></td>
</tr>
<tr>
<td>Heart failure</td>
<td>3.04</td>
<td>2.43–3.81</td>
<td>&lt;0.0001</td>
<td>2.93</td>
<td>2.39–3.59</td>
<td>&lt;0.0001</td>
<td></td>
</tr>
<tr>
<td>LVH*</td>
<td>2.39</td>
<td>1.90–3.00</td>
<td>&lt;0.0001</td>
<td>2.67</td>
<td>1.95–3.63</td>
<td>&lt;0.0001</td>
<td></td>
</tr>
<tr>
<td>History of MI</td>
<td>2.22</td>
<td>1.88–2.61</td>
<td>&lt;0.0001</td>
<td>3.56</td>
<td>2.90–4.36</td>
<td>&lt;0.0001</td>
<td></td>
</tr>
<tr>
<td>African American race</td>
<td>0.75</td>
<td>0.62–0.91</td>
<td>0.003</td>
<td>0.65</td>
<td>0.55–0.76</td>
<td>&lt;0.0001</td>
<td></td>
</tr>
</tbody>
</table>

Table 2. Predictors of Incident AF in ARIC and CHS

Abbreviations as in Table 1.

* Determined by ECG using the Cornell voltage criteria.
had an adjusted 40% lower risk of AF (HR, 0.60; 95% CI, 0.49 to 0.74; P<0.001). In ARIC, African Americans had an adjusted 56% lower risk of AF (HR, 0.44; 95% CI, 0.27 to 0.72; P=0.001).

European Ancestry and Risk for AF
In CHS, 120 cases of incident AF occurred among 804 African Americans without AF at baseline after a median follow-up of 10 years (IQR, 5.5 to 10.5 years). The African American participants of CHS exhibited an average of 24±15% European ancestry per the IBC array. Every 10% increase in European ancestry was associated with a 13% increase in risk of AF (HR, 1.13; 95% CI, 1.004 to 1.27; P=0.043). After adjustment for age, sex, BMI, hypertension, diabetes mellitus, heart failure, left ventricular hypertrophy, history of myocardial infarction, and study site, every 10% increase in European ancestry was associated with a 16% increased risk of AF (HR, 1.16; 95% CI, 1.03 to 1.31; P=0.015). Adding baseline statin use, antihypertensive drug use, and alcohol intake as potential confounders to the multivariate model did not meaningfully change the results.

Of 3481 African Americans without baseline AF in ARIC followed up for a median of 16 years (IQR, 15 to 17 years), 181 developed incident AF. African Americans in ARIC had an average 17±11% European ancestry. In unadjusted analysis, European ancestry was associated with a higher risk of AF, but this did not reach statistical significance; according to the IBC array, the HR for each 10% increase in European ancestry was 1.12 (95% CI, 0.99 to 1.27; P=0.065). However, after adjustment for age, sex, BMI, hypertension, diabetes mellitus, heart failure, left ventricular hypertrophy, history of myocardial infarction, and study site, each 10% increase in European ancestry was found to be associated with a statistically significant 18% increased risk of incident AF (Figure). Adding baseline statin use, antihypertensive drug use, and alcohol intake as potential confounders to the multivariate model did not meaningfully change the results.

In the ARIC Study, we were able to confirm the relationship observed between European ancestry and the risk of AF using a second, higher-density genotyping array. Using 3192 unlinked AIMs from the Affymetrix 6.0 array, we observed results similar to the 1747 AIMs from the IBC array. With the Affymetrix 6.0 array in ARIC, every 10% increase in European ancestry was associated with a 20% increased risk of AF (95% CI, 1.03 to 1.39; P=0.017) after adjustment for age, sex, BMI, hypertension, diabetes mellitus, heart failure, left ventricular hypertrophy, history of myocardial infarction, and study site. Adding baseline statin use, antihypertensive drug use, and alcohol intake as potential confounders to the multivariate model did not meaningfully change the results.

A meta-analysis of the IBC array AIMs in CHS and ARIC revealed statistically significant results for both the unadjusted (HR, 1.13; 95% CI, 1.03 to 1.23; P=0.007) and adjusted (Figure) associations between European ancestry and incident AF. There was no evidence of heterogeneity in the unadjusted (P=0.92) or adjusted (P=0.73) meta-analysis.

Discussion
In 2 community-based, multiracial cohorts, African Americans had a lower incidence of AF despite a higher prevalence of many traditional risk factors for AF, including hypertension, diabetes mellitus, heart failure, and larger BMI. By taking advantage of admixture mapping, we found that an increasing percentage of European ancestry was associated with an increased risk of AF in African Americans. Our results were consistent across 2 distinct cohorts, genotyping assays, and analytic methods. Thus, racial differences in risk of AF between African Americans and whites appear to be genetically mediated.

Although risk factors for AF are well known, they do not explain all attributable risk for AF.27,28 In fact, it remains a mystery why some individuals with heart failure and large atria never develop AF, whereas others with less cardiovascular disease do. To the best of our knowledge, our study is the first to demonstrate that a quantitative assessment of European ancestry predicts AF onset. The finding persisted after accounting for standard AF risk factors. This suggests that either African ancestry provides some protective effect or something about European ancestry increases the risk. The fact that African Americans exhibit significantly less AF despite the preponderance of risk factors suggests that other mediators at work are likely quite powerful.

Of particular importance is that African Americans exhibited substantially less AF despite having an average larger BMI and more often having hypertension, diabetes mellitus, heart failure, and left ventricular hypertrophy. This apparent paradox between established AF risk factors and AF incidence suggests that the association between European ancestry and AF is due to some as-yet unknown factor. Presumably, however, the consequences of AF, particularly thromboembolic complications, would follow the same positive correlation with European ancestry. Future research can determine whether embolic strokes, myocardial infarctions attributed to thromboemboli, and tachycardia-induced cardiomyopathy are more common in white populations and/or those with more European ancestry.
That AF is inherited has been well described in families with rare mutations,29–31 and a family history of AF is known to be a risk factor for the disease, particularly in those with lone AF.32–34 However, the finding that European ancestry itself is an independent risk factor implies that the heritability of AF may be substantially broader in scope than previously recognized.

According to the “out of Africa” hypothesis, there was a single migration of modern Homo sapiens out of Africa, with a subsequent loss of genetic variation as that initial non-African founder population grew and expanded to the north and east.35,36 Indeed, genetic clusters often correspond closely to collections of geographically and linguistically similar populations.37 Mutations occur at a certain rate, and an uncommon mutation may become a relatively common variant if that mutation occurs in the founder of a group residing in a particular geographic area (such as the European subcontinent). For example, there is now good evidence that the original settlement of the whole region of Australia arose from a single founder group.38 It is therefore possible that a founding population of the European subcontinent brought a genetic variation that increased the propensity to AF. Because AF generally develops at an older age and is not immediately lethal, it is certainly plausible that this genetic propensity could be transmitted to offspring without substantial natural selection against the putative variant(s). However, this genetic difference may in fact have offered some as-yet unknown survival advantage in the European environment, with an increased risk of AF in older age representing a consequential byproduct.

Several previous studies have successfully leveraged clinically observed racial disparities in disease prevalence to identify genomic loci in other complex diseases. Admixture mapping studies have revealed loci associated with prostate cancer39 and hypertension40 in African American men. On the basis of epidemiological observations that, like AF, multiple sclerosis is more common in those with more European ancestry, a genomic locus for this poorly understood disease was successfully identified.41 A similar approach may be informative in AF.

Our study has several limitations. First, there may be residual confounding. For example, it is possible that more European ancestry resulted in phenotypic differences associated with cultural practices or socioeconomic status that may have affected AF risk or detection. One possibility is that those with more European ancestry had lighter skin pigmentation, which itself was associated some behavior or environmental exposure responsible for the increased AF risk. Indeed, because those with more European ancestry by definition had more ancestors from a different continent, there may have been behavioral factors inherent to different social or cultural norms that caused the differential AF risk. Second, our study did not include echocardiographic data. We relied on a clinical history of heart failure and ECG evidence of left ventricular hypertrophy. However, it is unlikely that data from echocardiograms would have changed our results; in fact, echocardiographic differences might provide information regarding potential mediators of the racial differences. Although a small difference, we previously reported that African Americans have a shorter left atrial diameter than whites, albeit no difference in left atrial volumes.41 Although our outcome was restricted to incident AF, prevalent AF for both studies was defined as AF present on the baseline ECG. Therefore, it is possible that some of those deemed to have incident AF in fact had a known previous history of AF. However, because the primary predictor was genetic, it would appear unlikely that the misclassification of some prevalent AF patients as incident AF patients would substantially affect the results. Finally, AF was ascertained via serial clinic visits and hospitalizations, so we cannot exclude the possibility that some paroxysmal AF patients or asymptomatic AF patients were misclassified as not having AF. Such misclassification would generally result in a type II error and therefore should not explain our positive findings. However, it is possible that race, or continental ancestry, is associated with different types of AF rather than a simple presence or absence of AF.

Conclusions

We found that European ancestry is a risk factor for incident AF. This suggests that some of the difference in AF risk across races is probably genetic and that unknown factors independent of recognized risk factors likely affect susceptibility to AF. Identification of these factors might reveal new avenues for treating and possibly preventing this important disease.

Acknowledgments

We wish to acknowledge the support of the National Heart, Lung, and Blood Institute (NHLBI) and the contributions of the research institutions, study investigators, field staff, and study participants in creating this resource for biomedical research. We would like to thank Drs Richard S. Cooper and Philip L. De Jager for providing the Nigerian and European American Affymetrix 6.0 genotype data sets, as well as Dr Nick Patterson and Arti Tandon for curating the list of AIMs on the Affymetrix 6.0 genotyping platform.

Sources of Funding

This work was made possible by grant KL2 RR024130 (G.M.M.) from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH). The CARe project (N01-HC-65226) involves 9 parent studies that contributed parent study data, ancillary study data, and DNA samples through the Massachusetts Institute of Technology–Broad Institute to create this genotype/phenotype database for wide dissemination to the biomedical research community. ARIC: University of North Carolina at Chapel Hill (N01-HC-55015), Baylor Medical College (N01-HC-55016), University of Mississippi Medical Center (N01-HC-55021), University of Minnesota (N01-HC-55019), Johns Hopkins University (N01-HC-55020), University of Texas, Houston (N01-HC-55022), University of North Carolina, Forsyth County (N01-HC-55018); R01HL087641, R01HL59367 and R01HL066949; National Human Genome Research Institute contract U01HG004402; and National Institutes of Health contract HHSN268200625226C. Infrastructure was partly supported by grant UL1RR025005, a component of the NIH and NIH Roadmap for Medical Research. This study was also supported by grant RC1-HL099452 from NIH/NHLBI and grant 09SDG2280087 from the American Heart Association. CHS: University of Washington (N01-HC-85079), Wake Forest University (N01-HC-85080), Johns Hopkins University (N01-HC-85081), University of Pittsburgh (N01-HC-85082), University of California, Davis (N01-HC-85083), University of California, Irvine (N01-HC-85084), New England Medical Center (N01-HC-85085), University of Vermont (N01-HC-85086), Georgetown University (N01-HC-85087).
Disclosures

None.

References


Although atrial fibrillation (AF) is the commonest sustained arrhythmia encountered in clinical practice, the exact origin of the disease remains poorly understood. Previous data suggest that African Americans have a lower risk of AF despite a higher burden of AF risk factors, and it is not known whether this is due to environmental or genetic factors. Because African Americans represent a population admixed with African and European ancestry, we sought to test the hypothesis that a greater degree of European American ancestry is associated with a greater risk of AF. African Americans in both the Cardiovascular Health Study (CHS) and the Atherosclerosis Risk in Communities (ARIC) Study had a significantly lower risk of AF despite more commonly exhibiting AF risk factors. Using ancestral informative markers from the ITMAT-Broad-CARE array, we found that increasing European ancestry was independently associated with incident AF in both cohorts. Using ancestral informative markers from the Affymetrix 6.0 array in ARIC, we found similar results. This is the first study to demonstrate that European ancestry is an independent risk factor for AF. The paradoxical finding that whites have more AF despite fewer AF risk factors suggests that something associated with European ancestry, presumably a genetic variant, is a common and powerful component in determining propensity to AF independently of traditional risk factors such as hypertension, diabetes mellitus, heart failure, and obesity.
European Ancestry as a Risk Factor for Atrial Fibrillation in African Americans

doi: 10.1161/CIRCULATIONAHA.110.958306

_Circulation_ is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2010 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/content/122/20/2009

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in _Circulation_ can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to _Circulation_ is online at:
http://circ.ahajournals.org//subscriptions/